212 related articles for article (PubMed ID: 32488676)
1. Siponimod (Mayzent) Downregulates RhoA and Cell Surface Expression of the S1P1 and CX3CR1 Receptors in Mouse RAW 264.7 Macrophages.
Uosef A; Vaughn N; Chu X; Elshawwaf M; Abdelshafy AAA; Elsaid KMK; Ghobrial RM; Kloc M
Arch Immunol Ther Exp (Warsz); 2020 Jun; 68(3):19. PubMed ID: 32488676
[TBL] [Abstract][Full Text] [Related]
2. Macrophage/monocyte-specific deletion of Ras homolog gene family member A (RhoA) downregulates fractalkine receptor and inhibits chronic rejection of mouse cardiac allografts.
Liu Y; Chen W; Wu C; Minze LJ; Kubiak JZ; Li XC; Kloc M; Ghobrial RM
J Heart Lung Transplant; 2017 Mar; 36(3):340-354. PubMed ID: 27692539
[TBL] [Abstract][Full Text] [Related]
3. Siponimod (BAF312) Activates Nrf2 While Hampering NFκB in Human Astrocytes, and Protects From Astrocyte-Induced Neurodegeneration.
Colombo E; Bassani C; De Angelis A; Ruffini F; Ottoboni L; Comi G; Martino G; Farina C
Front Immunol; 2020; 11():635. PubMed ID: 32322257
[TBL] [Abstract][Full Text] [Related]
4. Fingolimod (FTY720) prevents chronic rejection of rodent cardiac allografts through inhibition of the RhoA pathway.
Chen W; Chen W; Chen S; Uosef A; Ghobrial RM; Kloc M
Transpl Immunol; 2021 Apr; 65():101347. PubMed ID: 33131698
[TBL] [Abstract][Full Text] [Related]
5. Siponimod in the treatment of multiple sclerosis.
Goodman AD; Anadani N; Gerwitz L
Expert Opin Investig Drugs; 2019 Dec; 28(12):1051-1057. PubMed ID: 31603362
[No Abstract] [Full Text] [Related]
6. Morpholino Analogues of Fingolimod as Novel and Selective S1P
Stepanovska B; Zivkovic A; Enzmann G; Tietz S; Homann T; Kleuser B; Engelhardt B; Stark H; Huwiler A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899717
[TBL] [Abstract][Full Text] [Related]
7. S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onset.
Pelz A; Schaffert H; Diallo R; Hiepe F; Meisel A; Kohler S
Eur J Immunol; 2018 Mar; 48(3):498-508. PubMed ID: 29205338
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
Chun J; Giovannoni G; Hunter SF
Drugs; 2021 Feb; 81(2):207-231. PubMed ID: 33289881
[TBL] [Abstract][Full Text] [Related]
9. Bone regenerative potential of the selective sphingosine 1-phosphate receptor modulator siponimod: In vitro characterisation using osteoblast and endothelial cells.
Sartawi Z; Ryan KB; Waeber C
Eur J Pharmacol; 2020 Sep; 882():173262. PubMed ID: 32534075
[TBL] [Abstract][Full Text] [Related]
10. S1P analogues SEW2871, BAF312 and FTY720 affect human Th17 and Treg generation ex vivo.
Zehra Okus F; Busra Azizoglu Z; Canatan H; Eken A
Int Immunopharmacol; 2022 Jun; 107():108665. PubMed ID: 35255303
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
Bravo GÁ; Cedeño RR; Casadevall MP; Ramió-Torrentà L
Cells; 2022 Jun; 11(13):. PubMed ID: 35805142
[TBL] [Abstract][Full Text] [Related]
12. Sphingosine-1-Phosphate Prevents Egress of Hematopoietic Stem Cells From Liver to Reduce Fibrosis.
King A; Houlihan DD; Kavanagh D; Haldar D; Luu N; Owen A; Suresh S; Than NN; Reynolds G; Penny J; Sumption H; Ramachandran P; Henderson NC; Kalia N; Frampton J; Adams DH; Newsome PN
Gastroenterology; 2017 Jul; 153(1):233-248.e16. PubMed ID: 28363640
[TBL] [Abstract][Full Text] [Related]
13. ST-2191, an Anellated Bismorpholino Derivative of Oxy-Fingolimod, Shows Selective S1P
Stepanovska Tanturovska B; Zivkovic A; Imeri F; Homann T; Kleuser B; Stark H; Huwiler A
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500564
[TBL] [Abstract][Full Text] [Related]
14. Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date.
Gajofatto A
Drug Des Devel Ther; 2017; 11():3153-3157. PubMed ID: 29138536
[TBL] [Abstract][Full Text] [Related]
15. To fingolimod and beyond: The rich pipeline of drug candidates that target S1P signaling.
Chew WS; Wang W; Herr DR
Pharmacol Res; 2016 Nov; 113(Pt A):521-532. PubMed ID: 27663260
[TBL] [Abstract][Full Text] [Related]
16. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
McGinley MP; Cohen JA
Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020
[TBL] [Abstract][Full Text] [Related]
17. Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling.
Gatfield J; Monnier L; Studer R; Bolli MH; Steiner B; Nayler O
Cell Signal; 2014 Jul; 26(7):1576-88. PubMed ID: 24704119
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of the sphingosine-1 phosphate receptor agonist siponimod on disrupted blood brain barrier function.
Spampinato SF; Merlo S; Sano Y; Kanda T; Sortino MA
Biochem Pharmacol; 2021 Apr; 186():114465. PubMed ID: 33577891
[TBL] [Abstract][Full Text] [Related]
19. Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate.
Liu S; Paknejad N; Zhu L; Kihara Y; Ray M; Chun J; Liu W; Hite RK; Huang XY
Nat Commun; 2022 Feb; 13(1):731. PubMed ID: 35136060
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory effects of siponimod on astrocytes.
Ogasawara A; Takeuchi H; Komiya H; Ogawa Y; Nishimura K; Kubota S; Hashiguchi S; Takahashi K; Kunii M; Tanaka K; Tada M; Doi H; Tanaka F
Neurosci Res; 2022 Nov; 184():38-46. PubMed ID: 35940437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
